# Perrigo Company plc (PRGO) Stock Analysis: Exploring a Potential 48.20% Upside with a High Dividend Yield

- Link: https://www.directorstalkinterviews.com/perrigo-company-plc-prgo-stock-analysis-exploring-a-potential-48-20-upside-with-a-high-dividend-yield/4121233551
- Published: 2026-01-06T11:15:32+00:00
- Author: Madison Wilson

Perrigo Company plc (NASDAQ: PRGO) stands as a significant player in the healthcare
sector, specifically within the specialty and generic drug manufacturing industry.
Headquartered in Dublin, Ireland, Perrigo’s extensive portfolio of over-the-counter
health and wellness solutions caters to markets across the United States, Europe,
and beyond. Despite recent financial challenges, the company presents intriguing
opportunities for individual investors, particularly those seeking high dividend
yields and potential growth.

Currently trading at $14.17, Perrigo’s stock has experienced a considerable decline
from its 52-week high of $29.47. This drop might concern some investors, but it 
also opens the door for potential value investments, especially with analysts suggesting
a target price range between $18.00 and $28.00. This suggests a substantial potential
upside of 48.20% from its current trading price. The average target price sits at
$21.00, indicating that the market may be underestimating Perrigo’s value.

Perrigo’s valuation metrics offer a mixed bag. The forward P/E ratio stands at a
modest 5.08, pointing to the stock being relatively undervalued compared to its 
peers. However, the absence of trailing P/E, PEG, and other traditional valuation
metrics, alongside a negative EPS of -0.21, reflects the company’s ongoing challenges
in profitability. Yet, despite these hurdles, Perrigo’s free cash flow remains robust
at approximately $358 million, providing a cushion for operations and dividends.

Investors should take note of Perrigo’s impressive dividend yield of 8.19%, which
is particularly attractive in the current low-interest-rate environment. However,
the astronomical payout ratio of 10,950% raises questions about the [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
of such dividends. This anomaly suggests that the company may be paying out more
than it earns, possibly drawing from reserves or cash flow to maintain its dividend
policy. This approach could be risky if the company’s financial performance does
not improve.

From a technical standpoint, Perrigo’s stock is trading below its 50-day and 200-
day moving averages, at $14.94 and $22.53, respectively. The RSI (Relative Strength
Index) of 44.65 indicates that the stock is neither overbought nor oversold, providing
no immediate signals of reversal but suggesting caution as the stock trends sideways.
The MACD (Moving Average Convergence Divergence) and its signal line further reinforce
this neutral sentiment.

Despite these mixed signals, the majority of analysts covering Perrigo maintain 
a cautious stance, with two buy ratings and three hold ratings, and no sell recommendations.
This suggests that while there is optimism for Perrigo’s recovery and growth, analysts
are also aware of the potential risks involved.

Perrigo’s diverse product lineup, spanning respiratory, nutrition, digestive health,
pain relief, oral care, and more, positions it well to capitalize on the growing
demand for self-care products. Its well-known brands, such as Mederma, Nasonex, 
and REACH, are household names, enhancing its market presence.

As Perrigo navigates its financial headwinds, investors should weigh the potential
high rewards against the inherent risks. The company’s ability to leverage its strong
market position and cash flow could drive future growth, but maintaining dividend
payouts and improving profitability will be critical. For those seeking high yields
with a tolerance for volatility, PRGO offers a compelling, albeit cautious, opportunity.

Share on:
